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Efficacy and safety of apremilast in
patients with mild-to-moderate plaque
psoriasis: Results of a phase 3,
multicenter, randomized, double-blind,
placebo-controlled trial
Linda Stein Gold, MD,a Kim Papp, MD, PhD,b,c David Pariser, MD,d Lawrence Green, MD,e Neal Bhatia, MD,f
Howard Sofen, MD,g,h Lorne Albrecht, MD,b,i,j Melinda Gooderham, MSc, MD,b,k,l Mindy Chen, MS,m
Maria Paris, MD,m Yao Wang, MD,m and Kristina Callis Duffin, MD, MSn
West Bloomfield, Michigan; Waterloo, Peterborough, and Kingston, Ontario, Canada; Norfolk, Virginia;
Washington, DC; San Diego, Los Angeles, and Thousand Oaks, California; Surrey and Vancouver, British
Columbia, Canada; and Salt Lake City, Utah
Background: Patients with mild-to-moderate psoriasis may have substantial quality-of-life impairment.
Objective: To evaluate apremilast 30 mg twice daily for mild-to-moderate psoriasis.
Methods: Phase 3, double-blind, placebo-controlled study in adults with mild-to-moderate psoriasis
inadequately controlled or intolerant to $ 1 topical psoriasis therapy (NCT03721172). The primary
endpoint was the achievement of static Physician Global Assessment score of 0 (clear) or 1 (almost clear)
and $ 2-point reduction at week 16.
Results: Five hundred ninety-five patients were randomized (apremilast: 297; placebo: 298). The primary
endpoint was met, with a significantly greater static Physician Global Assessment response rate observed at
week 16 in the apremilast group compared with the placebo group (21.6% vs 4.1%; P \ .0001). All
secondary endpoints were met with the achievement of body surface area-75 (33.0% vs 7.4%), body surface
area # 3% (61.0% vs 22.9%), $ 4-point reduction in Whole Body Itch Numeric Rating Scale (43.2% vs
18.6%), Scalp Physician Global Assessment 0 or 1 and $ 2-point reduction (44.0% vs 16.6 %), and changes
from baseline in body surface area, Psoriasis Area and Severity Index, and Dermatology Life Quality Index
(all P \ .0001). The most commonly reported adverse events ($ 5%) with apremilast were diarrhea,
headache, nausea, nasopharyngitis, and upper respiratory tract infection, consistent with prior studies.
Limitations: The study lacked an active-comparator arm.
Conclusion: Apremilast demonstrated efficacy in mild-to-moderate psoriasis and safety consistent with the
established safety profile of apremilast. ( J Am Acad Dermatol 2022;86:77-85.)
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INTRODUCTION

apremilast was efficacious for moderate-to-severe
Quality-of-life (QOL) impairment may be subplaque psoriasis, including psoriasis in special areas
stantial in patients with mild-to-moderate psoriasis,
such as the scalp.14-18 The Apremilast as a
even though they have less overall skin involvement
Direct Treatment for Mild-to-Moderate Plaque
than patients with morePsoriasis Versus Placebo trial
severe disease.1 Psoriasis
(ADVANCE; NCT03721172)
CAPSULE SUMMARY
is the first prospective,
that affects special areas,
phase 3, multicenter, randomsuch as the scalp or nails, is
ized, double-blind, placeboan example of relatively
Patients with mild-to-moderate psoriasis
controlled study of apremilast
limited skin lesions associreport high quality-of-life impairment
for mild-to-moderate psoriaated with moderate-to-high
despite limited skin involvement.
sis. The objective was to evaldisease burden.2,3 Because
Apremilast demonstrated statistically
uate the efficacy and safety of
of the limited body surface
significant, clinically meaningful efficacy
apremilast 30 mg twice daily
area involved, these patients
as systemic treatment for mild-toversus placebo in patients
may be classified as having
moderate plaque psoriasis and safety
with mild-to-moderate psorimild or moderate disease.
consistent with prior clinical trials.
asis, based on static Physician
Symptoms such as itch also
Global Assessment (sPGA),
can be extremely botherpsoriasis-involved body sursome and impactful for paface area (BSA), and Psoriasis Area and Severity Index
tients with all levels of disease severity.1
(PASI) assessments.
Patients with mild-to-moderate psoriasis often
receive only topical therapy.1 Several classes of
topical treatments are available, including topical
METHODS
corticosteroids, retinoids, vitamin D analogs, calciStudy design
neurin inhibitors, dithranol, tar-based preparations,
The ADVANCE study was conducted in the United
and combination treatments.4,5 Topical treatments
States and Canada (Supplemental Fig 1; available via
have demonstrated efficacy and tolerability for mildMendeley at https://doi.org/10.17632/djj5s5nyxc.2).
to-moderate psoriasis6-9 and are the initial treatment
The study was registered on October 26, 2018 and
for patients with mild-to-moderate psoriasis.10
the first patient was enrolled on March 19, 2019.
However, for some patients, topical treatments may
Patients were randomized (1:1) to apremilast 30 mg
not achieve sufficient disease control or may be
twice daily or placebo for the first 16 weeks by
impractical to apply.11
permuted block randomization using centralized
Tolerability or safety issues may be associated
interactive response technology. Treatment assignwith topical treatments. These include the potential
ment was stratified by baseline sPGA (mild
immunosuppressive effects with corticosteroids;
[sPGA = 2]: approximately 30% of patients; moderate
teratogenicity with retinoids; effects on calcium
[sPGA = 3]: approximately 70% of patients).
metabolism with vitamin D analogs; skin irritation
The study drug was administered twice daily
and discoloration with dithranol; and staining and
(approximately 12 hours apart) without food or
malodor with tar-based treatments.5,12 These condrink restrictions and with titration over the first
cerns may make topical treatments unsuitable for
week to mitigate gastrointestinal side effects. All
patients with mild-to-moderate psoriasis.
patients received apremilast 30 mg twice daily from
Timely use of systemic treatment may help treat
weeks 16 to 32, followed by a 4-week post-treatment
patients who cannot tolerate topical therapies or
observational phase for patients who completed the
have an inadequate response, thus avoiding signifstudy or discontinued early.
icant QOL impairment. Systemic therapies are generThe study sponsor, persons responsible for
ally used for more-severe psoriasis in accordance
ongoing study conduct, and patients were blinded
with their labels; thus, there is a paucity of data on
to treatment allocation. The study was approved
systemic therapies for milder psoriasis.
by the institutional review board/ethics committee
Apremilast, an oral phosphodiesterase 4 inhibitor,
before commencement and was conducted in
is indicated for patients with moderate-to-severe
compliance
with
Good
Clinical
Practice,
plaque psoriasis who are candidates for phototherapy
International Council for Harmonisation Guideline
or systemic therapy.13 In phase 3 and 4 clinical trials,
E6, the Declaration of Helsinki, and regulatory
d

d
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Abbreviations used:
ADVANCE:

AE:
BSA:
BSA-75:
CMH:
DLQI:
ITT:
PASI:
QOL:
sPGA:
ScPGA:
TEAE:
WBI-NRS:

Apremilast as a Direct Treatment for
Mild-to-Moderate Plaque Psoriasis
Versus Placebo: an Analysis of Clinical
Safety and Efficacy
adverse event
psoriasis-involved body surface area
$75% improvement in psoriasisinvolved body surface area
Cochran-Mantel-Haenszel
Dermatology Life Quality Index
intent to treat
Psoriasis Area and Severity Index
quality of life
static Physician Global Assessment
Scalp Physician Global Assessment
treatment-emergent adverse event
Whole Body Itch Numeric Rating
Scale

requirements. Patients provided written informed
consent before study-related procedures. The protocol was amended twice to clarify inclusion criteria,
study assessments, and procedures based on comments from regulatory authorities. No patients were
enrolled before these amendments.
Patients
The ADVANCE study enrolled biologic-naive
adults ($ 18 years) with chronic plaque psoriasis
for $ 6 months before screening. Eligible patients
had mild-to-moderate plaque psoriasis (sPGA 2-3,
BSA 2%-15%, and PASI 2-15) inadequately controlled
with, or intolerant to, 1 or more topical therapies.
Patients with any condition that would present a
risk to the patient or confound the ability to interpret
study data were excluded. Patients with current or
planned concurrent use of topical therapy within
2 weeks of randomization also were excluded,
except for unmedicated skin moisturizers, which
were permitted for body lesions, but not within
24 hours before the clinic visit. Other exclusion
criteria included conventional systemic therapy or
phototherapy within 4 weeks of randomization and
the use of any investigational drug within 4 weeks
before randomization or 5 pharmacokinetic/pharmacodynamic half-lives if known (whichever is
longer).
Assessments
The primary efficacy endpoint was the proportion
of patients achieving sPGA of 0 (clear) or 1 (almost
clear) with a 2-point reduction or more from baseline
at week 16. The sPGA is an investigator-rated
assessment of overall disease severity, evaluated on
a 5-point scale (0 [clear] to 4 [severe]), including an
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assessment of the severity of erythema, scaling, and
plaque elevation.
The predefined secondary endpoints at week 16
were the achievement of $ 75% improvement in
BSA (BSA-75); change from baseline in BSA; change
from baseline in PASI; achievement of BSA # 3%
(baseline BSA [ 3%); Whole Body Itch Numeric
Rating Scale (WBI-NRS) response ($ 4-point reduction from baseline; baseline score $ 4); achievement
of Scalp PGA (ScPGA) of 0 (clear) or 1 (almost clear)
with a 2-point or greater reduction from baseline
(baseline ScPGA $ 2); and a change from baseline in
Dermatology Life Quality Index (DLQI) total score.
The proportion of patients achieving BSA # 1% was
a predefined exploratory endpoint. Post hoc analyses evaluated proportions of patients at week 16
who achieved a DLQI total score # 5, a DLQI total
score of 0 or 1, and a $ 5-point reduction in DLQI
total score (baseline score [ 5).
Safety was evaluated throughout the study,
including adverse events (AEs), discontinuations
due to AEs, and clinically significant changes in
physical examinations, vital signs, or laboratory
findings. Adverse events were recorded from the
time of informed consent to 28 days after the last
dose; thereafter, reported serious AEs with a suspected relationship to the study drug were recorded.
Statistical analysis
Sample size was calculated by assuming a 15%
response rate for placebo and a 20% dropout rate.
With approximately 574 patients randomized 1:1, the
study would randomize approximately 287 patients
to apremilast and approximately 287 to placebo. This
provided [ 90% power to detect a 15% betweengroup difference for the primary endpoint (2-sided
0.05 significance level).
Efficacy analyses were conducted in the intent-totreat (ITT) population (all randomized patients). The
safety population comprised all randomized patients
who received 1 or more doses of the study drug.
Primary and secondary endpoints analyzed at week
16 were hierarchically ranked for testing to control
the overall type 1 error rate at the 2-sided 0.05
significance level. The following sequence was used:
achievement of sPGA 0 (clear) or 1 (almost clear)
with a $ 2-point reduction from baseline, achievement of BSA-75, change from baseline in BSA,
change from baseline in PASI, achievement of
BSA # 3% (baseline BSA [ 3%), achievement of
$ 4-point reduction (improvement) from baseline in
WBI-NRS (baseline score $ 4), achievement of
ScPGA of 0 or 1 with $ 2-point reduction from
baseline (baseline score $ 2), and change from
baseline in DLQI total score.

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on February 16, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

J AM ACAD DERMATOL

80 Stein Gold et al

Primary and categorical secondary endpoints
were analyzed using the Cochran-MantelHaenszel (CMH) test, adjusting for stratification factor at randomization (missing values were imputed
using the multiple imputation method). Continuous
variables were analyzed using a mixed model for
repeated measures, with change from baseline as the
response variable. Treatment group, visit time,
treatment-by-time interaction, and stratification factor were included as fixed effects, with baseline
value as a covariate. Post hoc analyses of DLQI
responses were analyzed with CMH tests using
nonresponder imputation for missing data.

RESULTS
Patients and baseline characteristics
Patients were recruited between March 19 and
November 18, 2019. Five hundred ninety-five patients were randomized and analyzed in the ITT
population (apremilast, n = 297; placebo, n = 298). A
total of 504 patients completed the double-blind
phase (apremilast, n = 258; placebo, n = 246). The
safety analysis included 594 patients who received 1
or more doses of the study drug (apremilast, n = 298;
placebo, n = 296).
Primary reasons for discontinuation of apremilast
versus placebo were withdrawal by patient (6.1% vs
7.7%), lost to follow-up (4.4% vs 5.0%), AEs (2.4% vs
2.3%), lack of efficacy (0% vs 1.3%), noncompliance
with study drug (0.3% vs 0%), and other (0% vs 1.0%)
(Supplemental Fig 2).
Demographics and baseline characteristics were
generally similar between groups (Table I). Mean
age was 49.2 years in the apremilast group and
48.3 years in the placebo group. Almost half of the
patients were women (apremilast: 41.4%; placebo:
49.3%). In the apremilast and placebo groups, mean
WBI-NRS scores were 6.1 and 6.3, respectively. Most
patients had ScPGA $ 2 (71.4% and 66.8%).
Efficacy endpoints
The primary endpoint was met, with statistically
significantly greater and clinically meaningful
achievement of sPGA scores of 0 (clear) or 1 (almost
clear) and $ 2-point reduction from baseline with
apremilast compared with placebo at week 16
(21.6% vs 4.1%, P \.0001). Compared with placebo,
the sPGA response rate for apremilast was statistically significantly greater as early as week 2 (P \.05,
week 2; P \.0001, weeks 4 to 16; Fig 1).
Apremilast demonstrated statistically significant
and clinically meaningful improvements compared
with placebo on all secondary endpoints at week 16
(P\.0001). Achievement of BSA-75 response (33.0%
vs 7.4%) and BSA # 3% (61.0% vs 22.9%) was
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Table I. Baseline demographics and disease
characteristics
Parameter

Age in years, mean
(SD)
Female, n (%)
Body mass index,
mean (SD), kg/m2
Duration of plaque
psoriasis in years,
mean (SD)
sPGA score, n (%)
2 (Mild)
3 (Moderate)
BSA percentage,
mean (SD)
PASI score, mean (SD)
Whole Body Itch NRS
score, mean (SD)
Scalp involvement
(ScPGA score $ 2),
n (%)
DLQI total score,
mean (SD)
Prior treatment,
n (%)*
$1 conventional
systemic
treatment
$1 biologic
treatmenty

Placebo
n = 298

Apremilast
n = 297

Total
N = 595

48.3 (14.5) 49.2 (14.7) 48.7 (14.6)
147 (49.3) 123 (41.4) 270 (45.4)
30.9 (7.0) 31.2 (7.2) 31.1 (7.1)
16.9 (13.9) 16.9 (14.3) 16.9 (14.1)

91 (30.5) 91 (30.6) 182 (30.6)
207 (69.5) 206 (69.4) 413 (69.4)
6.3 (3.3)
6.4 (3.6)
6.4 (3.4)
6.5 (2.9)
6.3 (2.6)

6.4 (2.9)
6.1 (2.4)

6.5 (2.9)
6.2 (2.5)

199 (66.8) 212 (71.4) 411 (69.1)

9.8 (5.9)

9.9 (5.8)

9.9 (5.9)

30 (10.1)

35 (11.8)

65 (10.9)

1 (0.3)

1 (0.2)

0 (0)

BSA, Psoriasis-involved body surface area; DLQI, Dermatology Life
Quality Index; N, total randomized patients; n, patients in each
group; NRS, numeric rating scale; PASI, Psoriasis Area and Severity
Index; ScPGA, Scalp Physician Global Assessment; sPGA, static
Physician Global Assessment.
*Per the study inclusion criteria, all patients had received $1
topical therapy.
y
One patient with prior biologic treatment was enrolled in the
study despite not meeting the eligibility criteria. This was a
protocol deviation.

significantly greater with apremilast compared with
placebo (P \ .0001 for both; Fig 2). Statistically
significantly greater least-squares mean changes
from baseline were observed with apremilast
compared with placebo for BSA (3.45% vs
0.07%) and PASI (3.47 vs 0.54) (P \ .0001,
both). Achievement of BSA # 1% at week 16 was
31.7% in the apremilast group and 7.2% in the
placebo group (nominal P \ .0001). Achievement
of ScPGA response was greater with apremilast
compared with placebo (44.0% vs 16.6%,
P \.0001; Fig 2).
Apremilast showed greater achievement of WBINRS response compared with placebo at week 16
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Placebo (n=298)
Apremilast (n=297)

Patients, %

30

†
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†

21.6

†

†

16.1

16.2

1.7

3.1

4.1

12

16

8.1

*

10

1.4
0

0

2

1.0
4

8

Study Week

Fig 1. Proportion of patients achieving sPGA response (score of 0 or 1 with $ 2-point
improvement) over 16 weeks (intent-to-treat population; multiple imputation analysis). The
intent-to-treat population includes all randomized patients. Error bars represent 95% confidence interval. sPGA, Static Physician Global Assessment. *P \.05; yP \.0001 versus placebo
based on Cochrane-Mantele-Haenszel test (multiple imputation).

(43.2% vs 18.6%, P \ .0001). Least-squares mean
improvement from baseline in DLQI total score was
significantly greater with apremilast compared with
placebo at week 16 (5.2 vs 2.4, P \ .0001).
Significantly greater improvement in DLQI score was
observed with apremilast compared with placebo as
early as week 2 (Fig 3). Greater proportions of
patients achieved clinically meaningful DLQI responses with apremilast compared with placebo at
week 16, including mean change from baseline
exceeding the minimal clinically important difference (minimal clinically important difference, $ 4point reduction from baseline) for DLQI total
score,19 achievement of DLQI score # 5 (56.3%
vs 31.5%, nominal P \ .0001), DLQI score of 0 or 1
(22.3% vs 5.5%, nominal P \ .0001), and $ 5-point
DLQI reduction (60.7% vs 33.8%, nominal P\.0001).
Safety
During the placebo-controlled period, 195
(65.4%) of 298 patients in the apremilast group and
139 (47.0%) of 296 in the placebo group experienced
1 or more treatment-emergent AEs (TEAEs; Table II).
Few patients reported severe TEAEs (apremilast: 8 of
298 [2.7%]; placebo: 2 of 296 [0.7%]; Table II). The
most common TEAEs ($ 5%, either group) with
apremilast compared with placebo were diarrhea (49
of 298 [16.4%] vs 15 of 296 [5.1%]), headache (39 of
298 [13.1%] vs 15 of 296 [5.1%]), nausea (38 of 298
[12.8%] vs 13 of 296 [4.4%]), nasopharyngitis (22 of
298 [7.4%] vs 8 of 296 [2.7%]), and upper respiratory
tract infection (17 of 298 [5.7%] vs 15 of 296
[5.1%]) (Table II). Most TEAEs were mild-tomoderate. Onset of diarrhea, nausea, headache/
tension headache, and vomiting typically occurred

within the first month of treatment (Supplemental
Table I).
In the apremilast group, 1 of 298 (0.3%) patients
had serious TEAEs of angina pectoris and myocardial
ischemia. In the placebo group, serious TEAEs
occurred in 4 of 296 (1.4%) patients (congestive
heart failure and pneumonia [n = 1], pneumococcal
pneumonia [n = 1], migraine without aura [n = 1], and
ectopic pregnancy [n = 1]). The patient with the
TEAEs of angina pectoris and myocardial ischemia
had a prior history of hypertension and hypothyroidism and a BMI of 29.9 kg/m2, bordering on
obesity. No serious TEAEs of depression or suicidal
behavior were reported during the placebocontrolled period. Few TEAEs led to withdrawal of
the study drug (apremilast: 13 of 298 [4.4%]; placebo:
7 of 296 [2.4%]; Table II). No clinically significant
changes in physical examinations, vital signs, or
laboratory parameters were noted.

DISCUSSION
In this first phase 3 study of the efficacy and safety
of apremilast in patients with mild-to-moderate
plaque psoriasis, apremilast demonstrated clinically
meaningful and statistically significant improvements compared with placebo in overall psoriasis
severity, scalp psoriasis, and whole body itch. The
safety profile of apremilast in patients with mild-tomoderate psoriasis was consistent with prior clinical
trials in moderate-to-severe psoriasis.14-17
Unlike prior apremilast studies, the ADVANCE
study evaluated patients with mild-to-moderate psoriasis who are commonly seen in clinical practice. In
these patients, apremilast treatment was associated
with significantly greater achievement of sPGA,
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Placebo (n=298)

100
90
80
70
60

Apremilast (n=297)

*

61.0

*

50
40
30
20
10
0

*

43.2

*

44.0

33.0
22.9

18.6

16.6

7.4
WBI-NRS response‡

BSA ≤3%†

BSA-75 response

ScPGA response§

Fig 2. Proportions of patients achieving BSA-75, BSA # 3%, WBI-NRS, and ScPGA responses at
week 16 (intent-to-treat population; multiple imputation analysis). Categorical endpoints
analyzed by Cochran-Mantel-Haenszel test (multiple imputation); continuous endpoints
analyzed by mixed model for repeated measures. The intent-to-treat population represents
all randomized patients. Error bars represent 95% confidence interval. BSA, Psoriasis-involved
body surface area; BSA-75, $ 75% reduction from baseline in BSA; ScPGA, Scalp Physician
Global Assessment; WBI-NRS, Whole Body Itch Numeric Rating Scale. *P \ .0001 versus
placebo for all secondary endpoints; yIn patients with BSA [ 3% at baseline; zIn patients with
WBI-NRS $ 4 at baseline; xIn patients with ScPGA $ 2 at baseline.
Placebo

LS Mean Change
From Baseline in
DLQI Total Score‡

0

Apremilast

-1

-2.1

-2
-3

- 2.3

-2.4

-3.2

-4

*

-5

- 2.4

MCID
-4.2
†

-6
-7

- 2.3

- 4.7
†

- 5.2

-5.2

†

†

0

2

4

8
Study Week

12

16

298

282

284

274

256

249

Apremilast, n 297

2 81

2 87

269

2 64

261

N
Placebo, n

Fig 3. Least-squares mean change from baseline in DLQI total score over 16 weeks (intent-to-treat
population, mixed model for repeated measures). The intent-to-treat population represents all
randomized patients. A $ 4-point improvement from baseline is considered to be the MCID for
DLQI improvement.19 Error bars represent 95% confidence interval. DLQI, Dermatology Life
Quality Index; LS, least squares; MCID, minimal clinically important difference. *P \ .001;
y
P \ .0001 versus placebo based on mixed model for repeated measures analysis; zData as
observed for mean change from baseline in DLQI total score over time.

BSA-75, ScPGA, and WBI-NRS responses and greater
achievement of treatment targets based on National
Psoriasis
Foundation
recommendations
(ie,
BSA # 3% and BSA # 1%)20 compared with placebo.
Improvements in QOL outcomes were observed,
including greater achievement of DLQI minimal
clinically important difference19 and DLQI total score
# 5 with apremilast compared with placebo at week
16. Greater proportions of patients achieved minimal

to no impact of psoriasis on QOL with apremilast
compared with placebo at week 16.
Assessments of skin involvement, such as PASI,
may not adequately assess disease severity or
improvement in patients with mild psoriasis and
can be difficult to use in clinical practice.21 Although
patients in the ADVANCE study had mild-tomoderate psoriasis based on baseline sPGA, mean
BSA (apremilast: 6.4%; placebo: 6.3%), and mean
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Table II. Overview of TEAEs during the placebocontrolled phase in the safety population
Patients, n (%)

Overview of TEAEs
Any TEAE
Any severe TEAEs*
Any serious TEAEsy
Any TEAEs leading to drug
withdrawalz
Any TEAEs leading to death
Most commonly reported
($ 5% in any group)
TEAEs
Diarrhea
Headache
Nausea
Nasopharyngitis
Upper respiratory tract
infection

Placebo
n = 296

139
2
4
7

(47.0)
(0.7)
(1.4)
(2.4)

0 (0)

15
15
13
8
15

(5.1)
(5.1)
(4.4)
(2.7)
(5.1)

Apremilast
n = 298

195
8
1
13

(65.4)
(2.7)
(0.3)
(4.4)

0 (0)

49
39
38
22
17

(16.4)
(13.1)
(12.8)
(7.4)
(5.7)

TEAE, Treatment-emergent adverse event.
*TEAE severity was determined based on the investigator’s
judgment, and severe TEAEs included symptoms that caused
severe discomfort or pain; symptoms that required medical or
surgical attention or intervention; interference with activities of
daily living; or AEs requiring drug therapy.
y
Serious TEAEs were determined based on standardized
definitions and included AEs that resulted in death; were lifethreatening (i.e., in the opinion of the investigator, the patient is at
immediate risk for death from the AE); required inpatient
hospitalization or prolongation of existing hospitalization
(hospitalization is defined as an inpatient admission, regardless
of length of stay); resulted in persistent or significant disability/
incapacity (a substantial disruption of the patient’s ability to
conduct normal life functions); were congenital anomalies/birth
defects; or constituted an important medical event.
z
This table presents the number of patients who had any TEAEs
leading to drug withdrawal. Some of these patients discontinued
the study mainly due to the AEs, and these patients are reflected
in the patient disposition figure (Supplemental Fig 2) as
discontinuations due to AEs. However, some patients decided to
withdraw themselves from the study when a mild AE was reported
or after AEs that were quickly resolved. Based on the investigator’s
judgment, the main reason for study discontinuation in those
cases was noted as either withdrawal by patient or lost to followup. The safety population is defined as all randomized patients
who received $1 dose of study drug. TEAEs leading to drug
withdrawal in the apremilast group were abdominal pain, Crohn’s
disease, depression, eczema, diarrhea, fatigue, gastritis,
gastroenteritis, headache, myalgia, myocardial ischemia, nausea,
suicidal ideation, and vomiting. TEAEs leading to drug withdrawal
in the placebo group were abdominal pain, cough, diarrhea,
ectopic pregnancy, face edema, headache, nausea, pharyngeal
edema, pruritus, and psoriasis.

Nonetheless, baseline skin severity, scalp involvement (ScPGA $ 2), and mean DLQI scores were
lower among patients in the ADVANCE study
compared with patients with moderate-to-severe
psoriasis in the ESTEEM 1 and 2 phase 3 pivotal
trials and patients with moderate psoriasis in the
UNVEIL trial.14,15,17 Overall, the ADVANCE population was notably different from the pivotal ESTEEM
trials, as mean BSA and PASI were at least 3 times
higher in ESTEEM 1 and 2 versus ADVANCE,14,15 and
psoriasis duration and prior use of conventional
systemic treatments at baseline were lower in
ADVANCE versus ESTEEM 1 and 2.14,15 Despite these
differences, efficacy findings in ADVANCE were
generally consistent with those of ESTEEM 1 and
2.14,15 Safety findings in ADVANCE were consistent
with the known safety profile of apremilast.14,15 The
current study demonstrates that apremilast represents an effective systemic treatment option for
patients with mild-to-moderate psoriasis.
Topical treatments are commonly used to treat
mild-to-moderate psoriasis and have demonstrated
efficacy and tolerability in randomized clinical trials.6,7 However, guidelines suggest that systemic
treatment should be considered for patients with
mild-to-moderate skin involvement who experience
high disease burden or inadequate disease control
with topical therapies, including patients with psoriasis in special areas.
One limitation of this study is the lack of an activecomparator arm. This restricts the ability to make
direct comparisons with other systemic treatments.
The homogeneity of the study population limits its
generalizability to patients in the clinical setting.
These data should be complemented by real-world
data.

CONCLUSION
Apremilast significantly and clinically meaningfully reduced overall psoriasis severity and improved
scalp psoriasis, whole body itch, and QOL in patients
with mild-to-moderate plaque psoriasis. No new
safety findings were observed.14,15
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